ANX005

Phase 2Small molecule

AAnnexon, Inc.

ANX005 is one of 51 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Warm Autoimmune Hemolytic AnemiaActive, not recruiting

Warm Autoimmune Hemolytic Anemia (waiha)Completed

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Warm Autoimmune Hemolytic AnemiaPhase 2

Active, not recruiting

Warm Autoimmune Hemolytic Anemia (waiha)Phase 2

Completed

Competition

Competitive Landscape

220 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Radicava

Shionogi

Phase 3

2 3

Simdax

Orion Corporation, Orion Pharma

Phase 3

1 4

Robitussin

Ultomiris

Lithobid

SSolvay Pharmaceuticals

Phase 3

3 7

Minocin

TTriax

Phase 3

2 8

Sodium Valproate

AstraZeneca

Phase 3

1 9

BOTULINUM TOXIN TYPE B

Eisai

Phase 3

1 10

Namenda

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Huntington's Disease1 trial

An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

Completed·AAnnexon, Inc.·Phase 2·NCT04514367·28 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome

Completed·AAnnexon, Inc.·Phase 3·NCT04701164·242 enrolled

Single Dose1 trial

Single Dose Study of ANX005 in Healthy Volunteers

Terminated·AAnnexon, Inc.·Phase 1·NCT03010046·27 enrolled

AIN1 trial

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Completed·AAnnexon, Inc.·Phase 1·NCT04035135·14 enrolled

Amyotrophic Lateral Sclerosis1 trial

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

Completed·AAnnexon, Inc.·Phase 2·NCT04569435·17 enrolled

1 more indication

Warm Autoimmune Hemolytic Anemia (wAIHA)1 trial

A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)

Completed·AAnnexon, Inc.·Phase 2·NCT04691570·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for ANX005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ANX005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ANX005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Annexon, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAnnexon, Inc.

ANX005

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Huntington's Disease1 trial

Efficacy and Safety1 trial

Single Dose1 trial

AIN1 trial

Amyotrophic Lateral Sclerosis1 trial

Warm Autoimmune Hemolytic Anemia (wAIHA)1 trial

References

Drug Info

Quick Facts

Related News